Actively Recruiting
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Led by Sun Yat-sen University · Updated on 2025-08-14
240
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Atezolizumab + Bevacizumab was superior to sorafenib in overall survival in advanced hepatocellular carcinoma. The programmed cell death protein-1 (PD1) and PDL1 inhibitor, was effective and tolerable in patients with advanced hepatocellular carcinoma. We aimed to describe the efficacy and safety of locoregional therapy combined with Bevacizumab and PD1/L1 inhibitor in patients with advanced hepatocellular carcinoma who can not receive radical therapy.
CONDITIONS
Official Title
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed hepatocellular carcinoma by histopathology or clinical guidelines, including recurrent HCC after surgery
- Age between 18 and 75 years
- Stage B (middle) or Stage C (late) hepatocellular carcinoma according to Barcelona Clinic Liver Cancer staging
- Receiving locoregional therapy (TACE or HAIC) combined with Bevacizumab and PD1/L1 inhibitor as first-line or non-first-line therapy
- Child-Pugh liver function class A or B
- Eastern Cooperative Group performance status (ECOG) score of 0 to 2
- Hemoglobin level of at least 8.5 g/dL
- Total bilirubin level of 30 mmol/L or less
- Serum albumin level of at least 32 g/L
- AST and ALT levels no more than 5 times the upper limit of normal
- Serum creatinine level no more than 1.5 times the upper limit of normal
- INR 1.5 or less or prothrombin time and aPTT within normal limits
- Absolute neutrophil count greater than 1,500/mm3
- Prothrombin time 18 seconds or less or international normalized ratio less than 1.7
- Ability to understand and agree to the study protocol and provide written informed consent
You will not qualify if you...
- Cholangiocellular carcinoma (intrahepatic cholangiocarcinoma)
- Lack of imaging information
- Expected survival less than 3 months
- Serious other medical conditions
- Evidence of liver decompensation such as ascites, gastrointestinal bleeding, or hepatic encephalopathy
- Known HIV infection
- History of organ transplant
- Known or suspected allergy to study drugs or related agents
- Cardiac arrhythmias requiring anti-arrhythmic treatment
- Evidence of bleeding disorders
- Significant gastrointestinal bleeding within 30 days before study entry
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA hospital
Beijing, Beijing Municipality, China, 100853
Actively Recruiting
Research Team
Q
Qunfang Zhou, MD
CONTACT
F
Feng Duan, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here